---
title: 'The role of the thioredoxin/thioredoxin reductase system in the metabolic
  syndrome: towards a possible prognostic marker?'
type: pub
encoding: UTF-8

---
<h1>Publication</h1>
<article id="csl-bib-container-UGFCQMVP" class="csl-bib-container">
  <div class="csl-bib-body"> <div class="csl-entry">Tinkov, A. A., Bjørklund, G., Skalny, A. V., Holmgren, A., Skalnaya, M. G., Chirumbolo, S., &#38; Aaseth, J. (2018). The role of the thioredoxin/thioredoxin reductase system in the metabolic syndrome: towards a possible prognostic marker? <i>Cellular and Molecular Life Sciences (CMLS)</i>, <i>75</i>(9), 1567–1586. <a href="https://doi.org/10.1007/s00018-018-2745-8">https://doi.org/10.1007/s00018-018-2745-8</a></div> </div>
  <div class="csl-bib-buttons">
    <a href="#taxonomy-article-UGFCQMVP" alt="archive" class="csl-bib-button">Archive</a>
    <a href="https://app.cristin.no/results/show.jsf?id=1581022" alt="Cristin" class="csl-bib-button">Cristin</a>
    <a href="http://zotero.org/groups/5881554/items/UGFCQMVP" alt="Zotero" class="csl-bib-button">Zotero</a>
    <a href="#keywords-article-UGFCQMVP" alt="keywords" class="csl-bib-button">Keywords</a>
    <a href="#about-article-UGFCQMVP" alt="about_pub" class="csl-bib-button">About</a>
    <a href="#sdg-article-UGFCQMVP" alt="sdg" class="csl-bib-button">Sustainable Development Goals</a>
    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11105605" alt="Unpaywall" class="csl-bib-button">Unpaywall</a>
    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11105605" alt="EZproxy" class="csl-bib-button">EZproxy</a>
  </div>
  <div id="csl-bib-meta-container-UGFCQMVP"></div>
</article>
<div id="csl-bib-meta-UGFCQMVP" class="csl-bib-meta">
  <article id="about-article-UGFCQMVP" class="about_pub-article">
    <h1>About</h1>
    Tinkov et al. conducted a review exploring the thioredoxin/thioredoxin reductase (Trx/TrxR) system's role in metabolic syndrome, a cluster of conditions that increase the risk of heart disease, diabetes, and stroke. They found that this system, which involves proteins that help with cellular reactions, is crucial for processes like fat tissue function, carbohydrate metabolism, insulin production, blood pressure control, and inflammation. The study suggests that targeting the Trx/TrxR system could be beneficial in managing metabolic syndrome, insulin resistance, type 2 diabetes, hypertension, and atherosclerosis. Additionally, the authors propose that this system might serve as a marker to predict or diagnose metabolic syndrome, offering a potential new tool for healthcare providers.
  </article>
  <article id="keywords-article-UGFCQMVP" class="keywords-article">
    <h1>Keywords</h1>
    Thioredoxin Reductase, Metabolic Syndrome, Insulin Resistance, Type 2 Diabetes, Hypertension, Atherosclerosis
  </article>
  <article id="abstract-article-UGFCQMVP" class="abstract-article">
    <h1>Scientific abstract</h1>
    Mammalian thioredoxin reductase (TrxR) is a selenoprotein with three existing isoenzymes (TrxR1, TrxR2, and TrxR3), which is found primarily intracellularly but also in extracellular fluids. The main substrate thioredoxin (Trx) is similarly found (as Trx1 and Trx2) in various intracellular compartments, in blood plasma, and is the cell’s major disulfide reductase. Thioredoxin reductase is necessary as a NADPH-dependent reducing agent in biochemical reactions involving Trx. Genetic and environmental factors like selenium status influence the activity of TrxR. Research shows that the Trx/TrxR system plays a significant role in the physiology of the adipose tissue, in carbohydrate metabolism, insulin production and sensitivity, blood pressure regulation, inflammation, chemotactic activity of macrophages, and atherogenesis. Based on recent research, it has been reported that the modulation of the Trx/TrxR system may be considered as a new target in the management of the metabolic syndrome, insulin resistance, and type 2 diabetes, as well as in the treatment of hypertension and atherosclerosis. In this review evidence about a possible role of this system as a marker of the metabolic syndrome is reported.
  </article>
  <article id="sdg-article-UGFCQMVP" class="sdg-article">
    <h1>Sustainable Development Goals</h1>
    <div class="sdg-container"><div id="sdg3" class="sdg">
        <img src="{{< params subfolder >}}images/sdg/sdg03_en.png" class="image" alt="SDG 3">
        <div class="sdg-overlay">
          <a href="{{< params subfolder >}}en/archive/?sdg=3#archive" class="sdg-publication-count"><span>1377</span> Publications</a>
          <p><a href="https://sdgs.un.org/goals/goal3" class="sdg-read-more">Read More</a></p>
        </div>
      </div></div>
  </article>
  <article id="taxonomy-article-UGFCQMVP" class="taxonomy-article">
    <h1>Archive</h1>
    <ul>
      <li><a href="{{< params subfolder >}}en/archive/?key=3DCRN523">University of Inland Norway</a></li>
      <li><a href="{{< params subfolder >}}en/archive/?key=IDKFS3MX">Faculty of Social and Health Sciences</a></li>
      <li><a href="{{< params subfolder >}}en/archive/?key=GTV4ECMZ">Department of Health and Nursing Sciences</a></li>
      <li><a href="{{< params subfolder >}}en/archive/?key=676HMQBA">2018</a></li>
      <li><a href="{{< params subfolder >}}en/archive/?key=JSBENWRD">April</a></li>
    </ul>
  </article>
</div>
